caa a22 4500 475818490 CHVBK 20180406123815.0 cr unu---uuuuu 170329e20000901xx s 000 0 eng 10.1007/s002280000175 doi (NATIONALLICENCE)springer-10.1007/s002280000175 Högger P. Westfälische Wilhelms-Universität, Institut für Pharmazeutische Chemie, Hittorfstrasse 58-62, D-48149, Münster, Germany e-mail: hogger@uni-muenster.de Tel.: +49-251-8333347; Fax: +49-251-8332144, DE aut Adverse effects of opioid analgesic treatment are correlated with a significant elevation in plasma epinephrine in healthy humans [Elektronische Daten] [P. Högger] Objective: The purpose of this study was to elucidate the relationship of plasma catecholamine concentrations with experienced pain intensity and analgesic effects in the setting of an experimental pain study with human volunteers. Methods: Plasma norepinephrine and epinephrine concentrations of 12 healthy human volunteers were analysed before and during painful electrical tooth-pulp stimulation under medication using the highly potent opioid analgesic tilidine in a fixed tilidine/naloxone combination and with the non-steroidal anti-inflammatory agent bromfenac. Catecholamine levels were compared with pharmacodynamic effects and reported adverse effects. Results: Catecholamine levels revealed a statistically significant increase in plasma epinephrine concentrations (but not norepinephrine concentrations) 60-90 min after administration of tilidine/naloxone. This was correlated with the onset of adverse effects involving vertigo episodes in all reported cases. In contrast, there was no obvious correspondence of epinephrine or norepinephrine plasma concentrations to the experience of pain and analgesia. For comparison, under medication with the non-opioid analgesic bromfenac, only one mild adverse effects were noted, and no changes in plasma epinephrine or norepinephrine could be determined during the experimental sessions. Conclusions: It is proposed that elevated plasma epinephrine concentrations are a newly determined response to opioid-induced vertigo; this has possible clinical implications. Springer-Verlag Berlin Heidelberg, 2000 Key words Adverse effects nationallicence Epinephrine nationallicence Opioid analgesia nationallicence https://doi.org/10.1007/s002280000175 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280000175 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Högger P. Westfälische Wilhelms-Universität, Institut für Pharmazeutische Chemie, Hittorfstrasse 58-62, D-48149, Münster, Germany e-mail: hogger@uni-muenster.de Tel.: +49-251-8333347; Fax: +49-251-8332144, DE aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer